Cargando…

Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose

PURPOSE: Opioid-induced constipation (OIC) is a common side effect of opioid therapy. Methylnaltrexone (MNTX) is a selective, peripherally acting μ-opioid receptor antagonist, with demonstrated efficacy in treating OIC. We pooled results from MNTX clinical trials to compare responses to an initial d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chamberlain, Bruce H, Rhiner, Michelle, Slatkin, Neal E, Stambler, Nancy, Israel, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391063/ https://www.ncbi.nlm.nih.gov/pubmed/37533563 http://dx.doi.org/10.2147/JPR.S405825

Ejemplares similares

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies
por: Chamberlain, Bruce H, et al.
Publicado: (2021)

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials
por: Shah, Eric D, et al.
Publicado: (2023)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018)

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Correction to: The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation
por: Farchadi, David, et al.
Publicado: (2023)

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness
por: Mehta, Neel, et al.
Publicado: (2023)

Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials
por: Mehta, Neel, et al.
Publicado: (2023)

Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis
por: Webster, Lynn R, et al.
Publicado: (2022)

Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008)

The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies
por: Brenner, Darren M., et al.
Publicado: (2021)

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010)

Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
por: Saini, Harneel S, et al.
Publicado: (2020)

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2018)

Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
por: Bader, S., et al.
Publicado: (2011)

Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
por: Clemens, Katri Elina, et al.
Publicado: (2010)

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
por: Neefjes, Elisabeth CW, et al.
Publicado: (2014)

Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
por: Webster, Lynn R, et al.
Publicado: (2018)

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension
por: Bull, Janet, et al.
Publicado: (2015)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes
por: Siemens, Waldemar, et al.
Publicado: (2016)

Efficacy and Safety of Methylnaltrexone for the Treatment of Opioid-Induced Constipation: A Meta-analysis of Randomized Controlled Trials
por: Zhang, Ying-Ying, et al.
Publicado: (2021)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Publicado: (2018)

Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial
por: Webster, Lynn R., et al.
Publicado: (2017)

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis
por: Viscusi, Eugene R., et al.
Publicado: (2016)

Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial
por: Patel, Parind B., et al.
Publicado: (2020)

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)
por: Patel, Parind B, et al.
Publicado: (2016)

Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist
por: Uritsky, Tanya J.
Publicado: (2019)

Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department
por: Peacock, W. Frank, et al.
Publicado: (2022)

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial
por: Hanai, Akiko, et al.
Publicado: (2015)

70400 Collaborative Care for Opioid Dependence And Pain (CCODAP): A Pilot Randomized Control Trial of an Opioid Tapering Intervention
por: Bushey, Michael, et al.
Publicado: (2021)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus
por: Viscusi, Eugene R., et al.
Publicado: (2013)

Influence of Flax Seeds on the Gut Microbiota of Elderly Patients with Constipation
por: Ma, Jianxia, et al.
Publicado: (2022)

Methylnaltrexone bromide methanol monosolvate
por: Li, Guoqing, et al.
Publicado: (2012)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

4326 Effects of Single-dose Preoperative Pregabalin on Postoperative Pain and Opioid Consumption in Cleft Orthognathic Surgery
por: Said, Abdullah, et al.
Publicado: (2020)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis
por: Nelson, Kirbylee K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qnolh0j1t3tpgn0ejldockm9oo